Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Single-sequence, Self-controlled Open Design Study , to Investigate the Effects of Rifampicin and Clarithromycin on the Pharmacokinetics of RSS0343.

NCT07696091 is registered in ClinicalTrials.gov with Reistone Biopharma Company Limited as lead sponsor.

NCT NCT07696091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07696091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Single-sequence, Self-controlled Open Design Study , to Investigate the Effects of Rifampicin and Clarithromycin on the Pharmacokinetics of RSS0343.
Lead sponsor
Reistone Biopharma Company Limited
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
September 30, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-cystic fibrosis bronchiectasis、chronic sinusitis without nasal polyps、chronic obstructive pulmonary disease